These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 2457397)

  • 1. Reverse transcriptase activity (RTA) in lymphocyte cultures of HIV-infected patients receiving short treatments of HPA 23. A biological evaluation.
    Vittecoq D; Woerle R; Barre-Sinoussi F; Chermann JC
    Biomed Pharmacother; 1988; 42(1):35-9. PubMed ID: 2457397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reverse transcriptase activity (RTA) in lymphocyte cultures of AIDS patients treated with HPA-23.
    Buimovici-Klein E; Ong KR; Lange M; Englard A; McKinley GF; Reddy M; Grieco MH; Cooper LZ
    AIDS Res; 1986; 2(4):279-83. PubMed ID: 2434115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Addition of HPA 23 to cyclosporin in the treatment of thrombopenic purpura in HIV-positive subjects].
    Laporte JP; Meyohas MC; Eliaszewicz M; Najman A; Frottier J; Woehrle R
    Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):870-2. PubMed ID: 2443894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of HPA-23 antiviral activity in HIV-infected patients without AIDS.
    Burgard M; Sansonetti P; Vittecoq D; Descamps P; Guetard D; Herson S; Rozenbaum W; Rouzioux C
    AIDS; 1989 Oct; 3(10):665-8. PubMed ID: 2480798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of rabies in mice and foxes with antiviral compounds.
    Bussereau F; Picard M; Blancou J; Sureau P
    Acta Virol; 1988 Jan; 32(1):33-49. PubMed ID: 2897770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curdlan sulfate (CRDS) in a 21-day intravenous tolerance study in human immunodeficiency virus (HIV) and cytomegalovirus (CMV) infected patients: indication of anti-CMV activity with low toxicity.
    Gordon M; Deeks S; De Marzo C; Goodgame J; Guralnik M; Lang W; Mimura T; Pearce D; Kaneko Y
    J Med; 1997; 28(1-2):108-28. PubMed ID: 9249617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trial of tolerance of HPA-23 in patients with acquired immune deficiency syndrome.
    Moskovitz BL
    Antimicrob Agents Chemother; 1988 Sep; 32(9):1300-3. PubMed ID: 3058016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity of HPA-23 (ammonium-21-tungsto-9-antimoniate) for normal human myeloid progenitor cells (GM-CFU) in vitro.
    Aymard JP; Ferry R; Janot C; Schooneman F; Legras B; May T; Streiff F
    Biomed Pharmacother; 1989; 43(6):451-4. PubMed ID: 2590721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic trials with HPA23, alpha-IFN and ribavirin in AIDS patients.
    Moroni M; Lazzarin A; Orlando G; Crocchiolo P; Castagna A; Verani P
    Chemioterapia; 1987 Jun; 6(2 Suppl):639-41. PubMed ID: 3509513
    [No Abstract]   [Full Text] [Related]  

  • 10. Development of antiviral agents for the treatment of human immunodeficiency virus infection.
    Tartaglione TA; Collier AC
    Clin Pharm; 1987 Dec; 6(12):927-40. PubMed ID: 3322638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in the development of antiviral therapy for HTLV-III-associated diseases.
    Yarchoan R; Broder S
    Important Adv Oncol; 1987; ():293-311. PubMed ID: 2841232
    [No Abstract]   [Full Text] [Related]  

  • 12. In vivo effect of a new mineral condensed ion (HPA 39) on murine Friend leukaemia.
    Larnicol N; Augery Y; Le Bousse-Kerdiles C; Degiorgis V; Chermann JC; Teze A; Jasmin C
    J Gen Virol; 1981 Jul; 55(Pt 1):17-23. PubMed ID: 7299368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AIDS: the virus, antivirals and vaccines.
    Weber J
    Br J Hosp Med; 1987 Feb; 37(2):135-7, 140-1. PubMed ID: 2950962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Experimental chemotherapy of AIDS].
    Rada B
    Cas Lek Cesk; 1988 May; 127(22):677-83. PubMed ID: 3293790
    [No Abstract]   [Full Text] [Related]  

  • 16. Ammonium-5-tungsto-2-antimoniate (HPA23) can prevent fox rabies.
    Pepin M; Blancou J
    Arch Virol; 1985; 83(3-4):327-9. PubMed ID: 3970678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of suramin, HPA-23 and 3'-azidothymidine triphosphate on the reverse transcriptase of bovine leukaemia virus.
    Reimer K; Matthes E; Scholz D; Rosenthal HA
    Acta Virol; 1989 Jan; 33(1):43-9. PubMed ID: 2469327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular and molecular mechanisms of antiretroviral effects of HPA23.
    Dormont D; Yeramian P; Lambert P; Spire B; Daveloose D; Barre-Sinoussi FC; Chermann JC
    Cancer Detect Prev; 1988; 12(1-6):181-94. PubMed ID: 2460236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antiviral compound HPA-23 can prevent scrapie when administered at the time of infection.
    Kimberlin RH; Walker CA
    Arch Virol; 1983; 78(1-2):9-18. PubMed ID: 6686005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ammonium 5-tungsto-2-antimoniate on encephalomyocarditis and vesicular stomatitis virus infections in mice.
    Werner GH; Jasmin C; Chermann JC
    J Gen Virol; 1976 Apr; 31(1):59-64. PubMed ID: 177729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.